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B
reast cancer is the most common malignancy and a major cause of death in women (1) . Identification of novel biomarkers as noninvasive tools for the early diagnosis and follow-up of patients with breast cancer and/ or novel therapeutic targets are currently popular research topics.
Obesity has been associated with lower breast cancer risk in premenopausal women, but this association reverses after menopause, probably because of an estrogen factor phenomenon (2) . In addition to estrogens, growth factors, including activins and follistatins, may also link obesity with breast cancer. More specifically, IGF-1, a molecule inducing cell proliferation, was shown to be positively associated with increased breast cancer risk in premenopausal women (3, 4) , whereas serum insulin-like growth factor binding protein (IGFBP)-3 was shown to be inversely associated with breast cancer in a study of both pre-and postmenopausal females (5) .
The primary role of IGFBPs is to deliver IGFs to the target tissue, thereby regulating IGFs local bioavailability, thus possibly representing an intriguing antioncogenic target. For example, in the IGF-1/IGFBP-4/pregnancyassociated plasma protein (PAPP)-A axis, PAPP-A, a zinc metalloproteinase, proteolytically cleaves IGFBP-4, which subsequently liberates IGF-1 to bind to its receptors (6) . Serum PAPP-A levels were increased in patients with lung cancer compared with healthy controls (7) . However, the involvement of the IGF-1/IGFBP-4/PAPP-A axis in breast cancer pathophysiology has not been fully elucidated. In a previous study, PAPP-A immunopositivity in patients with stage I breast cancer was associated with early recurrence of the disease (8) . More recently, the expression of PAPP-A was shown to be increased in luminal B (a molecular subtype that is associated with poorer prognosis [9] ) breast carcinomas tissue specimens compared with luminal A specimens (a subtype associated with better prognosis) (10) .
Furthermore, activin A, a member of the TGF-b cytokine superfamily, was initially isolated in follicular fluid and was suggested as an FSH secretagogue (11) , but was later shown to also be involved in human adipogenesis (12) and muscle mass regulation (13) . Regarding breast cancer, activin A levels were higher in postmenopausal patients with breast cancer compared with controls (14) , as well as in metastatic breast cancer, compared with healthy blood donors (15) . On the other hand, literature on its sister molecule, activin B, is limited and its possible involvement in breast tumorigenesis is currently unknown. Additionally, follistatin and follistatin-like (FSTL)-3, which act as the natural antagonists of activin A and activin B, might exert differential effects in breast proliferative diseases, with higher expression of follistatin in benign breast tissue and higher expression of follistatinrelated gene (FLRG), which encodes FSTL-3, in malignant breast tissue (16) . At a molecular level, silencing of FLRG inhibited human breast cell proliferation (17) .
Currently, it is unknown whether these factors may be used as surrogate markers in the diagnosis of breast cancer. The main aim of this study was the comparative evaluation of serum activins, follistatins, and members of the IGF family levels in women with benign vs malignant breast neoplasms vs apparently healthy controls. The secondary aim was to study associations of these variables with anthropometric, demographic, or biochemical parameters.
Subjects and Methods

Study participants
This was a case-control study, which took place in the Breast Cancer Surgery Clinic of Theagenio Cancer Hospital, Thessaloniki, Greece, in a breast cancer prevention program. Individuals with or without breast cancer were recruited. Exclusion criteria were: age , 18 years, history of malignancy of any type including breast cancer, and the presence of any severe/ life-threatening or muscle-wasting disease. Demographic, anthropometric, and medical history data were evaluated and recorded. Disease-free individuals without history or clinical/ imaging suspicion of breast mass were recruited as controls. Women with recently identified suspicious breast neoplasms underwent surgery and were subsequently classified into either benign or cancer group based on histology. Tumor histological characteristics, i.e., tumor size, presence of lymph node or distant metastases, presence of estrogen, progesterone (PR) and human epidermal growth factor-2 receptors, the Elston-Ellis modification of Scarff-Bloom-Richardson grading system (18) , and disease staging with the TNM system using the seventh edition of the American Joint Committee on Cancer staging system manual (19) were recorded.
To evaluate the possible effects of chemotherapy on the molecules of interest, we additionally recruited a group of patients with known breast cancer who had undergone neoadjuvant chemotherapy within the last year and who were scheduled for surgical removal of the residual tumor.
Body mass index (BMI) was calculated as weight divided by height squared (kg/m 2 ). Early morning (8:00-9:00 AM) blood samples were collected the day before surgery for the benign and both cancer groups, and on a routine visit for the controls, after an overnight 12-hour fast. The study protocol was in accordance with the Declaration of Helsinki and was approved by the Theagenio Cancer Hospital and the Aristotle University of Thessaloniki Ethics Committees. The BIDMC Institutional Review Board also provided exempt approval. All participants provided a written informed consent.
Biochemical and hormonal measurements
Fasting blood glucose and lipid profile parameters were assessed using routine laboratory techniques. Total adiponectin was measured with radioimmunoassay. Novel and highly specific ELISA kits from Ansh Laboratories, Webster, TX were used for the quantification of: activin A, activin B, follistatin, FSTL-3, total-IGF-1, total IGFBP-4, and intact IGFBP-4. For PAPP-A measurement, we used the picoPAPP-A ELISA assay, which detects low concentrations of PAPP-A found in nonpregnant women and men. Assay characteristics, including sensitivity, intra-assay and interassay coefficients of variation are provided in an off-site data repository (20) .
Statistical analysis
Statistical analysis was performed with SPSS v20.0 for Windows (IBM Corp., Armonk, NY). Data for continuous variables are presented as mean 6 SD, unless otherwise stated, and data for categorical variables are presented as numbers and/or percentages, as appropriate. Normality of distribution of the continuous variables was assessed with Kolmogorov-Smirnov test. Not normally distributed variables were logarithmically transformed, when needed. One-way ANOVA or Kruskal-Wallis test were used for between-group comparisons in cases of more than two groups of continuous variables, with post hoc Bonferroni correction, if needed. Unadjusted bivariate correlations were calculated with Pearson or Spearman coefficient and partial coefficient was used for correlations adjusted for potential confounders. Linear regression analysis was performed to identify independent predictors of continuous variables, e.g., tumor size. Logistic regression analysis was used to identify independent predictors of breast malignancy. We selected to run a number of comparisons between: 1) noncancer (healthy controls and benign) vs treatment-naive patients with cancer; 2) noncancer (healthy controls and benign) vs all patients with cancer (treatment-naive and chemotherapy treated) to identify possible predictors of the presence of breast malignancy; 3) between benign and treatment-naive malignancy group to evaluate the noninvasive potential of a measured molecule to distinguish a benign breast mass from malignancy. The level of statistical significance was set at 0.05 for all analyses.
Results
Comparisons between study groups
Descriptive characteristics of the study participants are summarized in Table 1 . Age was lower in the benign group than in both cancer groups (P = 0.001 for treatment-naive, P = 0.01 for chemotherapy-treated group, respectively). Weight, height, and BMI were not different between groups. Glucose levels were higher in the cancer groups compared with the control group (P = 0.01 for treatment-naive, P = 0.03 for chemotherapy-treated group, respectively). Total cholesterol, triglyceride, and adiponectin levels were similar between groups. In unadjusted comparisons, substantial differences were observed between groups in activin A, activin B, FSTL-3, total IGFBP-4, PAPP-A, and total IGF-1. However, after adjusting for age, BMI, and glucose levels, substantial differences between groups remained robust for FSTL-3, intact and total IGFBP-4, PAPP-A, and total IGF-1 (Table 1 ). In pairwise comparisons in the fully adjusted model after controlling for age, BMI, and blood glucose levels, FSTL-3 levels were substantially lower in benign compared with control group (P = 0.02). Total IGFBP-4 and PAPP-A levels showed an increasing pattern across groups, with lower levels in the control group compared with both cancer groups for total IGFBP-4 (P = 0.04 for treatment-naive, P = 0.01 for chemotherapy-treated group, respectively) and substantial difference between the control group and the chemotherapy group for PAPP-A (P = 0.01). However, intact IGFBP-4 exhibited an opposite pattern, with substantially lower levels in the chemotherapytreated cancer group compared with disease-free subjects (P = 0.02). Total IGF-1 levels were lower in the controls compared with the treatment-naive cancer group, yet with borderline significance (P = 0.047) ( Table 1) .
Associations with the variables of interest in the control group
Unadjusted bivariate ( Table 2 , left-lower side) and partial correlation matrices, after adjustment for age (20) , age and BMI (20) as well as age, BMI, and blood glucose levels ( Table 2 , right-upper side) were used to identify associates of the circulating levels of the molecules of interest.
Serum activin A remained positively associated with activin B, FSTL-3, total IGFBP-4, and PAPP-A levels, whereas negatively associated with total IGF-1 and total cholesterol. Associations of activin A with follistatin, intact IGFBP-4, and BMI did not remain robust after adjustment for age (Table 2 ). In the fully adjusted model, serum activin B was positively associated with FSTL-3 and PAPP-A, whereas negatively associated with follistatin and total cholesterol ( Table 2) . Most of the unadjusted associations for follistatin did not remain robust after adjustment for age, with the exception of a positive correlation with BMI (20) . On the contrary, FSTL-3 remained substantially associated with both intact and total IGFBP-4 ( Table 2) . Total IGFBP-4 remained positively associated only with PAPP-A. PAPP-A showed a persistent negative correlation with both total cholesterol and triglycerides, and an association with total IGF-1 levels. No further associations of intact IGFBP-4 and total IGF-1 remained robust in the fully adjusted model (Table 2) .
Association with the presence of breast malignancy
Logistic regression models comparing noncancer participants (i.e., healthy controls and benign group) to treatment-naive cancer group patients were utilized to elucidate independent associates of malignancy in untreated individuals. In univariate models, FSTL-3 total IGFBP-4, and PAPP-A were substantially associated with the presence of breast cancer (Table 3 ). After sequential adjustments for possible covariates, total IGFBP-4 was the only variable that remained positively associated with the presence of malignancy, whereas the PAPP-A marginally lost significance. When cancer-free individuals were compared with both cancer (treatment-naive and chemotherapy treated) groups, total IGF-1, total IGFBP-4, and PAPP-A were positively associated with the presence of cancer, whereas intact IGFBP-4 levels showed an inverse association (20) .
These findings were confirmed in receiver operating characteristic (ROC) curve analyses ( Fig. 1) , in which total IGFBP-4 performed better than all other molecules [area under the receiver operating characteristic curve (AUROC) = 0.65; 95% CI = 0.58, 0.71]; P , 0.001). When a combined model of total IGFBP-4, total IGF-1, PAPP-A adjusted for age, BMI, glucose and activin A, activin B, follistatin, and FSTL-3 the results were similar AUROC = 0.71; 95% CI = 0.65, 0.77; P , 0.001.
Further binary logistic regression analysis between the benign and the treatment-naive cancer group was performed to identify independent predictors able to distinguish between breast malignancy and benign lesions (Table 4) , when a breast mass is diagnosed. In univariate analysis, age and serum FSTL-3 and total IGFBP-4 were substantially associated with the presence of malignancy. However, only FSTL-3 remained associated with the presence of breast cancer after adjusting for potential covariates in consecutive models (Table 4 ). The higher the FSTL-3, the higher is the risk of breast malignancy.
In ROC curve analyses ( 
Associations with tumor histological characteristics in treatment-naive cancer group
In the treatment-naive cancer group, a trend of a nonsignificant unadjusted association between FSTL-3 tumor size was observed (r = 0.21, P = 0.055). No other significant correlation with tumor size or Ki67 levels was observed (20) . However, by performing multivariate linear regression analysis, we found that Ln-transformed FSTL-3 was independently associated with tumor size, after adjusting for potential covariates (Table 5) .
Additionally, differences in the variables of interest according to Elston-Ellis grade and TNM staging systems were explored. Activin B levels were different across ElstonEllis grading groups (Grade 1: 73.41 6 12.95 pg/mL, Grade 2: 107.00 6 40.02 pg/mL, Grade 3: 95.70 6 43.67 pg/mL; P = 0.03). This was not evident, however, in comparisons across different TNM stages. Regarding the presence of estrogen, PR, and human epidermal growth factor-2 receptors, adiponectin was lower (P = 0.01) in the PR-positive subgroup compared with the PRnegative subgroup. No other substantial association was observed.
Discussion
The results of this study indicate that high total IGFBP-4 levels are associated with the presence of cancer in the general population and high FSTL-3 levels are associated with the presence of breast cancer compared with benign lesions and larger tumor size, independently of potential covariates. Overall, case-control comparisons showed that total IGFBP-4, and to a lesser extent total IGF-1 and PAPP-A, might indicate the presence of cancer in previously untreated individuals, however, when a suspicious breast mass is located with clinical examination or imaging, FSTL-3 serum levels could be more precisely used as a noninvasive biomarker to discriminate between benign vs malignant lesions. The association between circulating levels of growth factors, and more specifically components of the IGF system, and increased cancer risk is now well-established. Our group led the way in showing that serum IGF-1 and IGFBP-3 levels are associated with increased breast cancer risk (21) . In follow-up studies, the role of adiposetissue-secreted molecules, such as adiponectin, which is upstream of the IGF-1 system, was also identified (22) . However, it remains unknown whether more recently identified IGF binding proteins such as IGFBP-4 or other growth factors, and/or activins and follistatins, might represent a novel pathway linking obesity with breast cancer. We thus continued by conducting the current study including standard and novel molecules to elucidate whether the activin-follistatin system is involved in breast carcinogenesis. FLRG, which encodes FSTL-3, is expressed at high levels in several tissues including the skin, the lung, the testis, and the uterus and seems to exert different actions than follistatin (23) . Hence, its physiology as well as its implication in breast tumorigenesis is not fully understood. Looking for associates in the apparently healthy control group, thus minimizing the possibility of local tumor growth factors' release, we found that FSTL-3 is independently associated with both intact and total IGFBP-4, whereas associations with glucose and total IGF-1 seemed to be age-and BMI-dependent, respectively. Regarding breast cancer, previous studies have shown that FSTL-3 was highly expressed in invasive breast carcinomas specimens compared with non-neoplastic luminal epithelial cells (16) . In contrast, a recent study, which also evaluated FSTL-3 expression at the tissue level, supported that higher FSTL-3 intensity was inversely associated with tumor size, but it could not be used as a predictor of the disease relapse (24) . To the best of our knowledge, this is the first study exploring Boldface indicates significance.
Significant values only are presented in the multivariate analysis.
Model 1 includes age and glucose as covariates.
Model 2 includes age, glucose, and BMI as covariates.
Model 3 includes age, glucose, BMI, and Ln-activin B as covariates.
Model 4 includes age, glucose, BMI, and Ln-activin B, activin A, and follistatin as covariates.
Abbreviation: Ln, natural logarithm transformation. a Ln transformed.
serum FSTL-3 levels in breast proliferative diseases. Our results are in line with most previous data indicating a possible role of FSTL-3 in breast carcinogenesis. However, whether FSTL-3 could be used as a noninvasive biomarker for the presence of breast cancer warrants further research in larger populations.
Moreover, we have recently identified associates of the IGFBP-4/ stanniocalcin-2/PAPP-A axis in a cohort of young healthy individuals (25) . In the current study, we confirmed that total IGFBP-4 was independently positively associated with PAPP-A, whereas associations with age, BMI, glucose, triglyceride levels, and total IGF-1 were affected from potential covariates. Most importantly, we showed that total IGF-1, total and intact IGFBP-4, and PAPP-A are predictors of the presence of malignancy, and IGFBP-4 particularly might be associated with breast cancer, because its total levels progressively increased from the control to cancer groups, and were also independently associated with the presence of cancer in previously untreated subjects. IGFBP-4 is known to exert both IGF-dependent and IGF-independent actions (26) . However, there is paucity of data regarding its role in breast cancer. In a murine model, the presence of a protease-resistant IGFBP-4 that was not inactivated by PAPP-A proteolysis limited local IGF-1 bioavailability and subsequent inhibition of tumor growth (27) . In a different study, however, IGFBP-4 mRNA expression in breast cancer tissue was positively associated with better disease-free and overall survival (28) . In clinical studies, Boldface indicates significance.
Significant predictors for FSTL-3 only are presented in the multivariate models. our group has previously shown substantially higher IGFBP-4 levels in breast cancer cases compared with patients with benign lesions of the breast, used as controls in that cohort (5) . However, in that study, tumor histological characteristics were not presented and at that time ELISA kits for the determination of both total and intact IGFBP-4 were not commercially available. We now confirm these findings, by additionally recruiting disease-free and chemotherapytreated subjects and elucidating that total IGFBP-4 might be used as a noninvasive screening biomarker for breast cancer. Together with total IGF-1 and PAPP-A, these molecules constitute the IGF-1/IGFBP-4/PAPP-A axis and might represent novel diagnostic tools for the early diagnosis of breast cancer in the general population. However, this hypothesis needs to be tested in future longitudinal studies recruiting larger sample size.
Other members of the TGF-b superfamily may be also involved in breast cancer development. In a recent consortium study of 10 prospective cohorts, antiMüllerian hormone (AMH), which also belongs to the TGF-b family, was identified as a possible biomarker of breast tumorigenesis in premenopausal females (29) . AMH is produced by granulosa cells with peak levels in the third decade of life, corresponding to peak fertility, and then gradually declines to depletion, becoming undetectable after menopause (30) . Higher AMH levels in premenopausal females may be associated with menopause at a later age, thus a potentially higher risk of breast cancer because of longer exposure to sex steroids (31) . Although intriguing, AMH could not be measured practically in our cohort that includes predominantly postmenopausal women, thus AMH levels would have been very low or undetectable. The diagnostic accuracy of AMH in predicting breast cancer risk should, however, be evaluated in future case-control and/or prospective studies with premenopausal women.
The strengths of our study are its novelty and the simultaneous comparative evaluation of several activins, follistatins, and growth factors using highly specific ELISA kits. We enrolled disease-free individuals and patients with newly diagnosed, histologically proven benign or malignant breast lesions with no prior treatment, as well as patients with known history of malignancy treated with neoadjuvant chemotherapy within the last year.
A limitation of the study is its case-control design, which cannot prove causality. However, our data do provide important background information, including the identification of specific markers that could be used in the design and interpretation of future prospective, mechanistic, and/or interventional studies. These studies are expected to elucidate the pathophysiologic role and the diagnostic potential of these molecules. Moreover, the design of this study does not allow direct comparison of the diagnostic accuracy of the introduced molecules toward imaging methods currently used for the screening of breast cancer, for which head-to-head studies are needed. In a meta-analysis, the AUROC for the detection of breast cancer was 0.79 for mammography and 0.93 for magnetic resonance imaging (32) . In another metaanalysis, the AUROC for contrast-enhanced ultrasonography was 0.91 (33) . Other authors showed that adding ultrasonography to mammography increased AUROC from 0.78 to 0.91 (34) . AUROC of our study (0.70) was lower than the aforementioned ones. However, this represents an indirect comparison. Furthermore, imaging studies carry a substantial individual variability because of different breast volume and parenchyma characteristics (35) . Therefore, it would be important to investigate in future studies whether the combination of circulating biomarkers with mammography and/or ultrasonography may increase the diagnostic accuracy of breast cancer and overcome the methodological limitations of the latter. In addition, because these molecules have not been incorporated in everyday practice, their cost could not be estimated at this point. If our results are validated and the molecules enter in clinical practice, head-to-head comparative studies are required with other methods currently used in the screening algorithm to provide costeffectiveness information. Finally, our study recruited patients from one breast cancer center, therefore, a selection bias may have occurred; multicenter studies are needed to limit ethnic or socioeconomic factors. Although we recruited a considerable sample size, larger studies in different populations are needed to validate our observations.
In conclusion, among a panel of studied activins, follistatins, and growth factors, higher levels of the total IGF-1/total IGFBP-4/PAPP-A axis members and primarily total IGFBP-4, as well as higher FSTL-3 levels were independently linked with the presence of breast malignancy. Higher FSTL-3 was also independently linked with larger tumor size. We suggest that measuring total IGF-1, PAPP-A, and primarily total IGFBP-4 in the general population might indicate the presence of breast cancer. However, when a suspicious breast mass is identified, measuring serum FSTL-3 might perform better in distinguishing breast cancer from a benign lesion. These results warrant mechanistic studies to elucidate any role of these molecules in breast carcinogenesis. If validated, cohort studies are needed to reveal their efficacy as noninvasive diagnostic markers, in addition to the current diagnostic tools.
